Revenue
2024
2025
| 2025 | 2024 | |
|---|---|---|
| Revenue | $39,990 | $83,000 |
| Research & development | $3.6M | $3.0M |
| Operating expenses | $58.3M | $7.2M |
| Operating income | −$58.2M | −$7.1M |
| Net income | −$62.1M | −$11.9M |
| Basic EPSper diluted share | -$3.20 | -$0.69 |
| Diluted EPSper diluted share | -$3.20 | -$0.69 |
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 1, 2026Form 4 | Heshmatpour Amir FPresident | BuyCommon Stock | 10.0K | $4.16 | $41.6K | 3.07M |
| Apr 28, 2026Form 4 | Heshmatpour Amir FPresident | BuyCommon Stock | 10.0K | $4.52 | $45.2K | 3.06M |
| Apr 23, 2026Form 4 | Neman-Ebrahim YoushaChief Clinical Officer | BuyCommon Stock | 500 | $4.88 | $2.4K | 134.8K |
| Apr 23, 2026Form 4 | Heshmatpour Amir FPresident | BuyCommon Stock | 10.0K | $4.90 | $49.0K | 3.05M |
| Apr 10, 2026Form 4 | Heshmatpour Amir FPresident | BuyCommon Stock | 10.0K | $4.90 | $49.0K | 3.04M |